QC
JSPR icon

Quadrature Capital’s Jasper Therapeutics JSPR Stock Holding History

Quadrature Capital’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-67,267
Closed -$123K – 1634
2025
Q4 		$123K Buy
+67,267
New +$135K ﹤0.01% 1065

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

Quadrature Capital's JSPR Position: Q1 2026 in Review

Quadrature Capital sold out of Jasper Therapeutics (JSPR) in Q1 2026, closing a stake of 67,267 shares — an estimated $123K sold.

Quadrature Capital first reported a position in JSPR in Q4 2025 and held it in 1 quarter. The position peaked at $123K in Q4 2025. 58 funds tracked by Wall St. Rank hold JSPR as of Q1 2026.

  • Quadrature Capital reported no remaining Jasper Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Quadrature Capital sold 67,267 Jasper Therapeutics shares in Q1 2026, an estimated $123K.
  • Quadrature Capital first reported a position in Jasper Therapeutics in Q4 2025 and held it in 1 quarter.
  • Quadrature Capital's Jasper Therapeutics position peaked at $123K in Q4 2025.
  • 58 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q1 2026.

Based on Quadrature Capital's 13F filing for Q1 2026, filed 15 May 2026.